ContributorsPublishersAdvertisers

Sintilimab With Bevacizumab Biosimilar and Chemotherapy Extends PFS in EGFR-NSCLC

targetedonc.com
 2021-11-22

Cover picture for the articleCompared with chemotherapy alone combination of sintilimab (Tyvyt) plus a bevacizumab biosimilar injection and chemotherapy significantly improves progression-free survival in EGFR NSCLC. The combination of sintilimab (Tyvyt) plus a bevacizumab biosimilar injection (IBI305, Byvasda) and chemotherapy significantly improves progression-free survival (PFS) in patients with EGFR-mutated non-small cell lung cancer...

www.targetedonc.com

Comments / 0

Comments / 0